Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 for Prevention of Oral Persistent HPV Infection in Adult Males
2022-501974-21-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection comparing Gardasil 9 with Placebo (2 arms). Planned start Nov 2022; status: authorised.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2022-501974-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501974-21-00.